R
René Adam
Researcher at Université Paris-Saclay
Publications - 634
Citations - 44864
René Adam is an academic researcher from Université Paris-Saclay. The author has contributed to research in topics: Liver transplantation & Transplantation. The author has an hindex of 92, co-authored 578 publications receiving 37929 citations. Previous affiliations of René Adam include University of Padua & University of Paris.
Papers
More filters
Journal ArticleDOI
Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation
Marc-Antoine Allard,Mylène Sebagh,Aldrick Ruiz,Catherine Guettier,Catherine Guettier,Bernard Paule,Eric Vibert,Antonio Sa Cunha,Antonio Sa Cunha,Daniel Cherqui,Daniel Cherqui,Didier Samuel,Didier Samuel,Henri Bismuth,D. Castaing,D. Castaing,René Adam,René Adam +17 more
TL;DR: In cirrhotic patients with HCC, a complete or nearly complete PR improves long-term survival after LR and LT independently of other pathological factors, underlines the importance of neoadjuvant treatment to obtain a significant decrease of active tumor load.
Journal ArticleDOI
Salvage Versus Primary Liver Transplantation for Early Hepatocellular Carcinoma: Do Both Strategies Yield Similar Outcomes?
Prashant Bhangui,Marc Antoine Allard,Eric Vibert,Daniel Cherqui,Gilles Pelletier,Antonio Sa Cunha,Catherine Guettier,Jean-Charles Duclos Vallee,Faouzi Saliba,Henri Bismuth,Didier Samuel,Denis Castaing,René Adam +12 more
TL;DR: In initially transplantable HCC-cirr patients, ITT survival was better in group PLT compared with group LR, and post SLT, short and long-term outcomes were comparable with PLT.
Journal ArticleDOI
Cetuximab plus Gemcitabine-Oxaliplatin (GEMOX) in Patients with Refractory Advanced Intrahepatic Cholangiocarcinomas
Bernard Paule,Marie-Olga Herelle,Estelle Rage,Michel Ducreux,René Adam,Catherine Guettier,Marie-Pierre Bralet +6 more
TL;DR: Even in the absence of EGFR gene amplification, cetuximab + GEMOX is a well-tolerated palliative treatment in patients with advanced CCA.
Journal ArticleDOI
Ischemic preconditioning for major liver resection under vascular exclusion of the liver preserving the caval flow: a randomized prospective study.
Daniel Azoulay,Valerio Lucidi,Paola Andreani,Umberto Maggi,Mylène Sebagh,Philippe Ichai,Antoinette Lemoine,René Adam,Denis Castaing +8 more
TL;DR: IP does not improve liver tolerance to ischemia-reperfusion after hepatectomy under vascular exclusion of the liver with preservation of the caval flow and this maneuver does not improved postoperative liver function and does not affect morbidity or mortality rates.
Journal ArticleDOI
Liver transplantation for HBV-related cirrhosis in Europe: An ELTR study on evolution and outcomes
Patrizia Burra,Giacomo Germani,René Adam,Vincent Karam,Alfredo Marzano,Pietro Lampertico,Mauro Salizzoni,Franco Filipponi,Jürgen Klempnauer,Denis Castaing,Murat Kilic,Luciano De Carlis,Peter Neuhaus,Sezai Yilmaz,Andreas Paul,Antonio Daniele Pinna,Andrew K. Burroughs,Francesco Paolo Russo +17 more
TL;DR: Outcomes of LT for HBV have improved in recent years, with disease recurrence being no longer a significant cause of death/graft loss.